Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

TRDA

NASDAQ

Entrada Therapeutics (TRDA)

6.86 USD −2.00% vs prior close
Entrada Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Market cap
268.6M USD
Revenue, year to Dec 2025
25.4M USD
EPS, diluted, year to Dec 2025
−3.47 USD
52-week range
5 USD – 16.08 USD
Avg volume
94.3K

as of Jul 17, 2026

Have Entrada Therapeutics (TRDA) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Entrada Therapeutics insiders reported 24 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 20 May 2026.

Form 4, 90 days to 22 Nov 2026, newest reported trade 9 Sep 2026

0buys
24sells
$7.20Mnet sold
4other filings
Have Entrada Therapeutics (TRDA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
09 Sep 2026MPM BioVentures 2014, L.P.10% OwnerSell28,837206K USD
09 Sep 2026MPM BIOVENTURES 2018, L.P.10% OwnerSell28,837206K USD
08 Sep 2026MPM BioVentures 2014, L.P.10% OwnerSell192,5001.4M USD
08 Sep 2026MPM BIOVENTURES 2018, L.P.10% OwnerSell192,5001.4M USD
04 Sep 2026MPM BioVentures 2014, L.P.10% OwnerSell38,500274K USD
04 Sep 2026MPM BIOVENTURES 2018, L.P.10% OwnerSell38,500274K USD
03 Sep 2026MPM BioVentures 2014, L.P.10% OwnerSell32,263231K USD
03 Sep 2026MPM BIOVENTURES 2018, L.P.10% OwnerSell32,263231K USD
02 Sep 2026MPM BioVentures 2014, L.P.10% OwnerSell25,131181K USD
02 Sep 2026MPM BIOVENTURES 2018, L.P.10% OwnerSell25,131181K USD
01 Sep 2026MPM BioVentures 2014, L.P.10% OwnerSell29,088205K USD
01 Sep 2026MPM BIOVENTURES 2018, L.P.10% OwnerSell29,088205K USD
Sold24 open-market sales991,894$7.20M

Showing the 12 most recent of 24 open-market trades in this window. The figures above count all of them.

4 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Entrada Therapeutics (TRDA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
02 Sep 2026Doshi DipalCEOTax withheld8,72462K USD
02 Sep 2026Dowden Nathan JPresident & COOTax withheld2,52818K USD
02 Sep 2026WENTWORTH KORY JAMESChief Financial OfficerTax withheld1,73312K USD
02 Sep 2026Sethuraman NatarajanPresident, Research & Develop.Tax withheld2,07915K USD

Which funds hold Entrada Therapeutics (TRDA)?

8 of the 45 institutional funds we track reported a Entrada Therapeutics position for the quarter ended 30 Sep 2026 — a combined 44.9M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Entrada Therapeutics (TRDA)?
FundPositionSharesValueShares q/q
Baker Bros. AdvisorsHeld (±25%)5,072,73032.2M USD
AQR Capital ManagementHeld (±25%)623,8744.0M USD−10.8%
Citadel AdvisorsHeld (±25%)461,7372.9M USD+17.1%
Millennium ManagementTrimmed344,6032.2M USD−54.9%
Renaissance TechnologiesHeld (±25%)199,2001.3M USD+4.3%
D. E. Shaw & Co.Added157,227998K USD+385.3%
Two Sigma InvestmentsAdded111,489708K USD+140.3%
Point72 Asset ManagementAdded101,727646K USD+256.9%

What has been filed or recorded for Entrada Therapeutics (TRDA)?

The filings we hold for Entrada Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 21 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Entrada Therapeutics (TRDA)?
And
21 Oct 2026Fails to deliverShares failed to deliver1,031 shares5K USD notional · 0.003% of shares out
19 Oct 2026Fails to deliverShares failed to deliver1,126 shares5K USD notional · 0.003% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.94 USDRevenue $1M
30 Sep 2026FinancialsTotal assets266.9M USDat period end
30 Sep 2026FinancialsTotal equity198.3M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −1.01 USDRevenue $1M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.95 USDRevenue $1M
31 Dec 2025Annual reportFY 2025 reportedEPS −3.47 USDRevenue $25M
31 Dec 2025FinancialsRevenue25.4M USDfiscal year
31 Dec 2025FinancialsNet income−143.8M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−3.47 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −1.06 USDRevenue $2M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −1.04 USDRevenue $2M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.42 USDRevenue $21M
31 Dec 2024Annual reportFY 2024 reportedEPS 1.68 USDRevenue $211M

What do people ask about Entrada Therapeutics (TRDA)?

From live data
What is Entrada Therapeutics’ market cap?268.6M

Entrada Therapeutics is worth 268.6M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is Entrada Therapeutics’ revenue?25.4M

Entrada Therapeutics reported revenue of 25.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Entrada Therapeutics insiders bought or sold shares recently?24 sales

In the 90 days to 22 Nov 2026, Entrada Therapeutics insiders reported 24 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 20 May 2026. A further 4 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Entrada Therapeutics?8 of 45

8 of the 45 funds we track reported a Entrada Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Baker Bros. Advisors, AQR Capital Management and Citadel Advisors. See Funds

When did Entrada Therapeutics last report earnings?−0.94

Entrada Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.94 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words